title: Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009-2010.
abstract: OBJECTIVE
  To determine the rates of fluoroquinolone resistant (FQR) in gram-negative bacilli urinary tract infections (UTIs) in a global population.
  
  
  METHODS
  The Study for Monitoring Antimicrobial Resistance Trends (SMART) collected 1,116 FQR gram-negative urinary pathogens from hospitalized patients in 33 countries during 2009-2010. Amikacin, ertapenem, and imipenem were the most active agents tested against FQR UTI pathogens, including extended-spectrum beta-lactamase producers.
  
  
  RESULTS
  FQR rates vary widely country to country with a range of 6% to 75%. Regional FQR rates were 23.5% in North America, 29.4% in Europe, 33.2% in Asia, 38.7% in Latin America, and 25.5% in the South Pacific.
  
  
  CONCLUSIONS
  These observations suggest that fluoroquinolones may no longer be effective as first-line therapy for gram-negative UTI in hospitalized patients.
authors.affiliation: International Health Management Associates, Inc., Schaumburg, IL, 60178 USA.
authors.forename: Sam
authors.initials: S
authors.lastname: Bouchillon
authors.forename: Daryl J
authors.initials: DJ
authors.lastname: Hoban
authors.forename: Robert
authors.initials: R
authors.lastname: Badal
authors.forename: Stephen
authors.initials: S
authors.lastname: Hawser